U.S. Membranous Nephropathy Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • Mar 2021
  • Country Level
  • 350 Pages
  • No of Tables: 15
  • No of Figures: 41

U.S. Membranous Nephropathy Market, By Disease Type (Primary Membranous Nephropathy, Secondary Membranous Nephropathy), Type (Diagnosis, Treatment), Cause (Autoimmune Disease, Hepatitis B and C, Cancer, NSAID Medications, Others), Population Type (Children, Adults), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) Industry Trends and Forecast to 2028

Market Analysis and Insights: U.S. Membranous Nephropathy Market

The membranous nephropathy market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.0% in the forecast period of 2021 to 2028 and is expected to reach USD 153.11 million by 2028. Increase in kidney disorders and ongoing research related to membranous nephropathy are the major drivers which have propelled the demand of the membranous nephropathy market in the forecast period.

Membranous nephropathy is a kind of kidney disorder in which the small blood vessels of the kidney known as glomeruli whose function is to filter the waste from the blood which gets thick and damaged. The condition leads to the excretion of excess protein in the urine which is known as proteinuria. It is a type of glomerular disease and autoimmune disease and membranous nephropathy is considered as one of the causes of nephrotic syndrome.

The increase in geriatric population in the United States and considered as target population for the membranous nephropathy may drive the membranous nephropathy market growth. The complications related to kidney transplantation and chances of recurrence of the membranous nephropathy in the patients may hamper the membranous nephropathy market of kidney transplantation. The increasing healthcare expenditure can lead to advancement in technologies and increase in the treatment options which may act as an opportunity for the growth of the membranous nephropathy market. The lack of skilled professionals can led to improper diagnosis and treatment which makes the process tedious and cumbersome and can lead to complications in patient if not treated which is the challenging factor for the growth of the membranous nephropathy market.

The membranous nephropathy market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the membranous nephropathy market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

U.S. Membranous Nephropathy Market Membranous Nephropathy Market Scope and Market Size

The membranous nephropathy market is segmented on the basis of disease type, type, cause, population type, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the membranous nephropathy market is segmented into primary membranous nephropathy and secondary membranous nephropathy. In 2021, primary membranous nephropathy segment is dominating the membranous nephropathy market because about 80% of cases are renal limited that is patient membranous nephropathy is associated with the other diseases.
  • On the basis of type, the membranous nephropathy market is segmented into diagnosis and treatment. In 2021, diagnosis segment is expected to dominate the membranous nephropathy market because membranous nephropathy is related to the excess protein in the urine so as far as patients go for common check, it may be diagnosed.
  • On the basis of cause, the membranous nephropathy market is segmented into autoimmune disease, hepatitis B and C, cancer, NSAID medications and others. In 2021, autoimmune disease segment is expected to dominate the membranous nephropathy market because several studies stated that the membranous nephropathy is majorly associated with the autoimmune disease.
  • On the basis of population type, the membranous nephropathy market is segmented into children and adults. In 2021, adults segment is expected to dominate the membranous nephropathy market because membranous nephropathy is common in older adults in their 50 to 60s though can occur earlier or later.
  • On the basis of end user, the membranous nephropathy market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, hospitals segment is dominating the membranous nephropathy market because of presence of highly specialized professional and presence of well-equipped technology for the treatment of nephropathy.
  • On the basis of distribution channel, the membranous nephropathy market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, hospital pharmacy segment is expected to dominate the membranous nephropathy market because hospital pharmacy has wide variety of medicines according to patient needs and demand.

Ongoing Research Regarding Membranous Nephropathy is boosting the Membranous Nephropathy Market Growth

The membranous nephropathy market also provides you with detailed market analysis for every country growth in membranous nephropathy industry with membranous nephropathy drugs sales, impact of advancement in the membranous nephropathy technology and changes in regulatory scenarios with their support for the membranous nephropathy market. The data is available for historic period 2011 to 2019.

Competitive Landscape and Membranous Nephropathy Market Share Analysis

The membranous nephropathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the U.S. membranous nephropathy market.

The major companies covered in the U.S. membranous nephropathy market report are Solco Healthcare, ALMATICA PHARMA LLC, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Novartis AG, Pfizer Inc., Viatris Inc., Avet Pharmaceuticals Inc., Teva Pharmaceutical USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Lupin Pharmaceuticals, Inc., Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Hikma Pharmaceuticals PLC, Accord Healthcare, Sun Pharmaceutical Industries Ltd., CareDx, Inc., Genentech, Inc. (a subsidiary of F. Hoffmann-La Roche Ltd), Azurity Pharmaceuticals, Inc., Fresenius Kabi USA (a subsidiary of Fresenius SE & Co. KGaA), Strides Pharma Science Limited, Alembic Pharmaceuticals Limited, AbbVie Inc. among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreement are also initiated by the companies’ worldwide which are also accelerating the membranous nephropathy market.

For instance,

  • In February 2019, Avet Pharmaceuticals Inc. announced the acquisition of 23 abbreviated new drug applications (ANDAs) which was already approved by the FDA. The products will be supplied by the third party and these products will be launched in the U.S. market. The acquisition has helped the company to increase their product portfolio which will increase their revenues in coming future.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market players is enhancing the company market in the membranous nephropathy market which also provides the benefit for organization to improve their offering for membranous nephropathy.

Customization Available: U.S. Membranous Nephropathy Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES 

TABLE 1 U.S. MEMBRANOUS NEPHROPATHY MARKET, PIPELINE ANALYSIS

TABLE 2 REGULATION IMPOSED BY FOOD AND DRUG ADMINISTRATION IN THE U.S.

TABLE 3 GENERIC DRUGS AND THEIR MANUFACTURING COMPANIES

TABLE 4 U.S. MEMBRANOUS NEPHROPATHYMARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 5 U.S. MEMBRANOUS NEPHROPATHYMARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 6 U.S. DIAGNOSIS IN MEMBRANOUS NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 7 U.S. DIAGNOSIS BY LABORATORY IN MEMBRANOUS NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 8 U.S. TREATEMNT IN MEMBRANOUS NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 9 U.S. TREATEMNT BY ACE-INHIBITOR IN MEMBRANOUS NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 10 U.S. TREATEMNT BY ANGIOTENSIN II RECEPTOR BLOCKERS IN MEMBRANOUS NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 11 U.S. TREATEMNT BY IMMUNOSUPPRESSIVE THERAPY IN MEMBRANOUS NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 12 U.S. TREATEMNT BY DIURETICS IN MEMBRANOUS NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 13 U.S. MEMBRANOUS NEPHROPATHYMARKET, BY CAUSE, 2019-2028 (USD MILLION)

TABLE 14 U.S. MEMBRANOUS NEPHROPATHYMARKET, BY CAUSE, 2019-2028 (USD MILLION)

TABLE 15 U.S. MEMBRANOUS NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions